These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 14534301

  • 1. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
    Williams RS, Chasman DI, Hau DD, Hui B, Lau AY, Glover JN.
    J Biol Chem; 2003 Dec 26; 278(52):53007-16. PubMed ID: 14534301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
    Fernandes VC, Golubeva VA, Di Pietro G, Shields C, Amankwah K, Nepomuceno TC, de Gregoriis G, Abreu RBV, Harro C, Gomes TT, Silva RF, Suarez-Kurtz G, Couch FJ, Iversen ES, Monteiro ANA, Carvalho MA.
    J Biol Chem; 2019 Apr 12; 294(15):5980-5992. PubMed ID: 30765603
    [Abstract] [Full Text] [Related]

  • 7. Detection of a novel mutation in exon 20 of the BRCA1 gene.
    Chakraborty A, Katarkar A, Chaudhuri K, Mukhopadhyay A, Basak J.
    Cell Mol Biol Lett; 2013 Dec 12; 18(4):631-8. PubMed ID: 24297685
    [Abstract] [Full Text] [Related]

  • 8. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
    Shiozaki EN, Gu L, Yan N, Shi Y.
    Mol Cell; 2004 May 07; 14(3):405-12. PubMed ID: 15125843
    [Abstract] [Full Text] [Related]

  • 9. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
    Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP.
    Genes Dev; 2002 Mar 01; 16(5):583-93. PubMed ID: 11877378
    [Abstract] [Full Text] [Related]

  • 10. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
    Ekblad CM, Wilkinson HR, Schymkowitz JW, Rousseau F, Freund SM, Itzhaki LS.
    J Mol Biol; 2002 Jul 12; 320(3):431-42. PubMed ID: 12096901
    [Abstract] [Full Text] [Related]

  • 11. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
    Drikos I, Nounesis G, Vorgias CE.
    Proteins; 2009 Nov 01; 77(2):464-76. PubMed ID: 19452558
    [Abstract] [Full Text] [Related]

  • 12. [Mapping of BRCT1 domain of BRCA1 with chromatin unfolding activity].
    Ye QN, Hu YF, Zhong HJ, Li R, Huang CF.
    Sheng Wu Gong Cheng Xue Bao; 2002 Nov 01; 18(6):656-61. PubMed ID: 12674632
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
    Gaiser OJ, Ball LJ, Schmieder P, Leitner D, Strauss H, Wahl M, Kühne R, Oschkinat H, Heinemann U.
    Biochemistry; 2004 Dec 28; 43(51):15983-95. PubMed ID: 15609993
    [Abstract] [Full Text] [Related]

  • 15. Effects of deletion and site-directed mutations on ligation steps of NAD+-dependent DNA ligase: a biochemical analysis of BRCA1 C-terminal domain.
    Feng H, Parker JM, Lu J, Cao W.
    Biochemistry; 2004 Oct 05; 43(39):12648-59. PubMed ID: 15449954
    [Abstract] [Full Text] [Related]

  • 16. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD.
    Eur J Hum Genet; 2008 Jul 05; 16(7):820-32. PubMed ID: 18285836
    [Abstract] [Full Text] [Related]

  • 17. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
    Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, Lenoir GM, Venezia ND.
    Oncogene; 2002 Oct 03; 21(44):6729-39. PubMed ID: 12360400
    [Abstract] [Full Text] [Related]

  • 18. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
    Yadegari F, Farahmand L, Esmaeili R, Zarinfam S, Majidzadeh-A K.
    J Biomol Struct Dyn; 2024 Jul 03; 42(11):5734-5746. PubMed ID: 37948190
    [Abstract] [Full Text] [Related]

  • 19. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat.
    Cortesi L, De Nicolo A, Medici V, Marino M, Turchetti D, Pradella LM, Rossi G, Parisini E, Federico M.
    Breast Cancer Res Treat; 2012 Jul 03; 134(1):435-41. PubMed ID: 22527099
    [Abstract] [Full Text] [Related]

  • 20. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
    Ekblad CM, Friedler A, Veprintsev D, Weinberg RL, Itzhaki LS.
    Protein Sci; 2004 Mar 03; 13(3):617-25. PubMed ID: 14978302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.